ARSENALBIO
ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs, and expanded market access.
ARSENALBIO
Industry:
Biotechnology Cloud Computing Life Science Medical
Founded:
2019-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.arsenalbio.com
Total Employee:
251+
Status:
Active
Contact:
650-240-8844
Total Funding:
305.81 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Euro Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Analytics Content Delivery Network Global Site Tag
Similar Organizations
BioFlyte
BioFlyte is a biodefense company created to commercialize a revolutionary new class of fieldable biological threat collection.
Calimmune
Calimmune is a clinical-stage gene therapy company.
EcoPlant
EcoPlant is a cloud based platform.
ExCellThera
ExCellThera is an advanced clinical stage biotechnology company.
Hemostemix
Hemostemix is a public clinical-stage biotechnology company.
Quell Therapeutics
Quell Therapeutics is a cell therapy company
Stemson Therapeutics
Stemson Therapeutics is a pre-clinical stage cell therapy company.
Turnstone Biologics
Turnstone Biologics is a privately-held clinical stage biotech company.
Aria Pharmaceuticals
Aria Pharmaceuticals is a artificial intelligence-driven biopharmaceutical company.
Current Advisors List
Board_member
Board_member
Current Employees Featured
Meg Nibbi Chief Legal Officer and Corporate Secretary @ ArsenalBio
Chief Legal Officer and Corporate Secretary
2021-05-01
Tarjei Mikkelsen Chief Technology Officer @ ArsenalBio
Chief Technology Officer
2019-10-01
Jane Grogan Chief Scientific Officer @ ArsenalBio
Chief Scientific Officer
2019-10-01
Jennifer McDevitt VP, Clinical Sciences @ ArsenalBio
VP, Clinical Sciences
2021-08-01
W. Nicholas Haining Co-Founder & Chief Scientific Officer @ ArsenalBio
Co-Founder & Chief Scientific Officer
2019-01-01
Ken Drazan Chairman, CEO, Co-Founder @ ArsenalBio
Chairman, CEO, Co-Founder
2019-01-01
Christopher Murriel Vice President, Pre-Clinical Pharmacology @ ArsenalBio
Vice President, Pre-Clinical Pharmacology
2022-01-01
Founder
Investors List
Euclidean Capital
Euclidean Capital investment in Series B - ArsenalBio
Parker Institute for Cancer Immunotherapy
Parker Institute for Cancer Immunotherapy investment in Series B - ArsenalBio
Bristol-Myers Squibb
Bristol-Myers Squibb investment in Series B - ArsenalBio
Emerson Collective
Emerson Collective investment in Series B - ArsenalBio
Westlake Village BioPartners
Westlake Village BioPartners investment in Series B - ArsenalBio
Kleiner Perkins
Kleiner Perkins investment in Series B - ArsenalBio
University of California, San Francisco
University of California, San Francisco investment in Series B - ArsenalBio
Triatomic Capital
Triatomic Capital investment in Series B - ArsenalBio
Hitachi Ventures
Hitachi Ventures investment in Series B - ArsenalBio
SoftBank Vision Fund
SoftBank Vision Fund investment in Series B - ArsenalBio
Key Employee Changes
| Date | New article |
|---|---|
| 2021-07-19 | ArsenalBio Strengthens Leadership Team with the Appointment of W. Nicholas Haining, BM, BCh, as Chief Scientific Officer |
Official Site Inspections
http://www.arsenalbio.com Semrush global rank: 1.54 M Semrush visits lastest month: 15.56 K
- Host name: 151.101.194.159
- IP address: 151.101.194.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ArsenalBio"
About - Arsenal Bio
Dr. Mikkelsen served as ArsenalBio's Chief Technology Officer from 2019 to December 2023. Prior to that, Dr. Mikkelsen held the position of Vice President, Biology at 10x Genomics, …See details»
ArsenalBio - Crunchbase Company Profile & Funding
ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much …See details»
ArsenalBio - The Org
ArsenalBio’s mission is to develop efficacious and safe cellular therapies for patients with chronic diseases, initially cancer. Industries. Biotechnology. Headquarters. South San Francisco, United States. Employees. 51-200. …See details»
Values - About Us
This is ArsenalBio. This is our Company. Ken Drazan, MD Founding CEO. Our Values. One Team We prioritize the team’s outcomes over individual goals to achieve our company mission together Transparency We operate with open …See details»
ArsenalBio - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 8, 2025 What are the most recent funding rounds of ArsenalBio? Its latest funding round was a Series C round on Jul 09, 2024 for $325M. 14 investors participated in its latest round, …See details»
Arsenal Bio Company Profile | Management and Employees List
Arsenal Bio Profile and History. Founded in 2019, ArsenalBio is a programmable cell therapy company creating immune cell therapies. They are focused on integrating technologies such …See details»
ArsenalBio - Leadership Team - The Org
The Leadership Team at ArsenalBio is responsible for steering the company's strategic vision and operational execution in the development of innovative cellular therapies for chronic diseases, …See details»
ArsenalBio - Company Profile & Staff Directory - ContactOut
ArsenalBio is a privately held, programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer. Our discovery engine comprises precise CRISPR …See details»
ArsenalBio - Contacts, Employees, Board Members, Advisors
ArsenalBio is a programmable cell therapy company that offers CAR T-cell therapies for solid tumors. New. Resources. ... Experience the new Crunchbase, powered by AI . Experience the …See details»
ArsenalBio | Company Overview & News - Forbes
ArsenalBio Company Stats. As of March 2024. Industry Biotechnology & Agriculture Founded 2018 Headquarters South San Francisco, California Country/Territory United States Chairman, …See details»
ArsenalBio 2025 Company Profile: Valuation, Funding & Investors
ArsenalBio was founded in 2018. Where is ArsenalBio headquartered? ArsenalBio is headquartered in South San Francisco, CA. What is the size of ArsenalBio? ArsenalBio has …See details»
Arsenal Bio - Overview, News & Similar companies - ZoomInfo
May 26, 2024 Who is Arsenal Bio. Founded in 2019, ArsenalBio is a programmable cell therapy company creating immune cell therapies. They are focused on integrating technologies suc h …See details»
Arsenal Biosciences - Craft
Arsenal Biosciences (ArsenalBio) is a programmable cell therapy company that develops tumor cell therapies to defeat cancer. It offers programmable immune cell therapies using cloud …See details»
Arsenal Bio
Mar 8, 2021 / ArsenalBio Announces Appointment of John Schroer as Chief Financial Officer and Tim Sirichoke as Chief Technical Operations Officer / Jan 7, 2021 / ArsenalBio Announces …See details»
ArsenalBio Strengthens Leadership Team with the Appointment of …
Jul 19, 2021 He also led a multi-disciplinary organization at Merck that focused on using innovative approaches to identify new therapeutic strategies for cancer and immunological …See details»
ArsenalBio emerges from stealth with $85 million and a
Oct 17, 2019 The story behind ArsenalBio begins with Sean Parker’s Institute for Cancer Immunotherapy.. Founded in 2016, the Institute has been instrumental in providing a space for …See details»
ArsenalBio Launches With $85 Million Series A Financing to …
Oct 17, 2019 South San Francisco, Calif., Oct. 17, 2019 – ArsenalBio makes its debut today backed by $85 million Series A financing to build a programmable cell therapy company to …See details»
ArsenalBio raises $325m for programmable CAR-T platform
Sep 5, 2024 Along with its in-house programmes, ArsenalBio has attracted some big-name pharma partners, including Bristol-Myers Squibb – a long-term investor – and …See details»
Establishing Canada’s first large-scale bioinnovation centre
2 days ago The Neptune BioInnovation Centre (NBC), a 51,000 sq ft facility on a 12.3 acre lot in Dartmouth, will offer leasable wet and dry lab space, warehouse and office spaces, and …See details»
Arsenal Biosciences Closes $220 Million Series B Financing to …
Sep 6, 2022 South San Francisco, Calif. – September 6, 2022 – Arsenal Biosciences, Inc. (ArsenalBio), a privately held programmable cell therapy company engineering advanced CAR …See details»